Lord Abbett & CO. LLC Has $51.73 Million Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

Lord Abbett & CO. LLC reduced its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 27.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 284,159 shares of the company’s stock after selling 108,079 shares during the quarter. Lord Abbett & CO. LLC owned about 0.99% of Krystal Biotech worth $51,726,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Key Financial Inc acquired a new position in Krystal Biotech during the second quarter valued at approximately $28,000. Blue Trust Inc. increased its stake in shares of Krystal Biotech by 2,328.6% in the 2nd quarter. Blue Trust Inc. now owns 170 shares of the company’s stock valued at $30,000 after purchasing an additional 163 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Krystal Biotech during the 3rd quarter worth $40,000. Values First Advisors Inc. bought a new stake in shares of Krystal Biotech during the 3rd quarter worth $53,000. Finally, Quest Partners LLC acquired a new stake in Krystal Biotech in the second quarter valued at about $71,000. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Trading Down 5.6 %

Shares of KRYS opened at $163.64 on Friday. The stock’s 50-day moving average price is $181.27 and its two-hundred day moving average price is $185.06. Krystal Biotech, Inc. has a 12 month low of $107.50 and a 12 month high of $219.34. The company has a market capitalization of $4.71 billion, a PE ratio of 92.45 and a beta of 0.80.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The company had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. During the same period in the previous year, the firm earned ($0.67) earnings per share. The firm’s quarterly revenue was up 879.9% on a year-over-year basis. Equities research analysts predict that Krystal Biotech, Inc. will post 2.97 EPS for the current fiscal year.

Analysts Set New Price Targets

KRYS has been the subject of several research analyst reports. Stifel Nicolaus boosted their target price on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. Citigroup increased their price objective on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. HC Wainwright reaffirmed a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a research note on Tuesday, December 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Finally, William Blair upgraded Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $206.67.

Insider Buying and Selling

In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the sale, the insider now owns 1,475,882 shares of the company’s stock, valued at $243,195,835.96. This trade represents a 1.67 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 14.10% of the stock is owned by insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).